Skip to main content
OpenTrials

Clinical trial condition

Stage IV Ovarian Cancer AJCC v8

Explore clinical trials studying Stage IV Ovarian Cancer AJCC v8. Study availability and eligibility vary by location and protocol.

32 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Stage IV Ovarian Cancer AJCC v8 trial results

Completed

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03707574

Conditions
Adnexal Diseases, Advanced Malignant Neoplasm, Advanced Melanoma, +85 more
Locations
  • Holy Cross Hospital Fort Lauderdale, Florida, United States
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia, United States
  • Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii, United States
  • Island Urology Honolulu, Hawaii, United States
View all 144 locations
View Trial Details
Active, Not Recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +60 more
Locations
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
  • Moffitt Cancer Center - McKinley Campus Tampa, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
View Trial Details
Active, Not Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Conditions
Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, +64 more
Locations
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

Conditions
Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions